Lp(a) blood test
Lipoprotein(a). Also called: Lipoprotein (a), Lipoprotein little a, Lp little a
Lp(a) is an LDL-like particle with an extra protein, apolipoprotein(a), attached. Its level is set mostly by your genes and stays fairly stable for life. The 2026 ACC/AHA guideline recommends measuring Lp(a) at least once in every adult, upgraded from the 2018 risk-enhancer-only framing.
An advanced lipid test, ordered on its own rather than as part of a standard Lipid Panel. The panel page explains when each test is ordered.
At a glance
| What it measures | The number of Lp(a) particles: LDL-like particles with apolipoprotein(a) bound to their ApoB. |
|---|---|
| Sample | Serum or plasma. Fasting is not needed. |
| Adult cut-offs | Below 75 nmol/L low risk; 75-125 intermediate or moderate; 125 or higher high (Labcorp, Quest). 125 nmol/L or 50 mg/dL is a risk-enhancing factor. |
| Peptides that move it | Injected IGF-1 (Insulin-Like Growth Factor 1) lowered it and Hexarelin raised it in small studies; MK-677 (Ibutamoren) and Insulin showed no change, and GnRH drugs gave mixed results. |
| Lab code | LOINC 43583-4 in nmol/L; 10835-7 in mg/dL (Labcorp 120188, Quest 34604) |
What is Lp(a)?
Lp(a) is an LDL-like particle: an ApoB-containing lipoprotein with a second protein, apolipoprotein(a), linked to it. Apolipoprotein(a) closely resembles plasminogen, a protein of the clotting system. High Lp(a) is a genetically determined, causal risk factor for heart attack and stroke, and for narrowing of the aortic valve.
How it is made and regulated
Where it is made
Lp(a) is assembled in the liver from apolipoprotein(a) and ApoB. Its level is set mainly by the LPA gene: by age 2 the gene is fully expressed, and adult levels are usually reached by about age 5. The number of kringle IV repeats in apolipoprotein(a) explains about 30-70% of the variation; small forms of the protein go with much higher levels.
What controls it
Few things change it. In the European consensus summary, fasting has no effect and physical activity little or none. Growth hormone therapy roughly doubles it and so does pregnancy; hypothyroidism raises it and treatment lowers it 5-20%; postmenopausal hormone therapy lowers it about 25%; nephrotic syndrome raises it 3-5 times.
How it travels in the blood
Labcorp and Quest measure Lp(a) with immunoturbidimetric assays and report it in nmol/L. Apolipoprotein(a) comes in many sizes, so results in mass units depend on the size of the protein; European experts recommend assays that are insensitive to size, and recommend reporting the assay name.
How long it lasts
Lp(a) is fairly stable over a lifetime, but one result can differ from the next by up to 20%, so the AHA statement suggests averaging two measurements for some patients. Levels stay constant in men and tend to rise in women at menopause.
What it does
Two common LPA gene variants that raise Lp(a) raised the odds of coronary disease by 1.70 and 1.92 times in a genetic study of thousands of patients and controls, evidence that Lp(a) itself causes disease. In the AHA statement's UK Biobank analysis, risk rose 11% for every 50 nmol/L.
Reference ranges
Lp(a) is read against risk categories. Labcorp and Quest print below 75 nmol/L as low or optimal and above 125 as high. US guidelines use 125 nmol/L or 50 mg/dL as a risk-enhancing factor; the 2022 European consensus rules risk out below 75 nmol/L (30 mg/dL) and in above 125 nmol/L (50 mg/dL).
Labcorp (test 120188)
| Group | Range (nmol/L) |
|---|---|
| Low Lp(a)-attributable risk | <75 |
| Intermediate | 75 to <125 |
| High, rising with higher values | 125 or higher |
As printed on Labcorp's sample report for test 120188 (a 35-year-old man, 2026). The reference interval is <75.0 nmol/L.
Quest Diagnostics (test 34604)
| Group | Range (nmol/L) |
|---|---|
| Optimal | <75 |
| Moderate | 75-125 |
| High | >125 |
Read from Quest's test directory for the East service area; Quest bases the cut points on Tsimikas (JACC 2017).
European Atherosclerosis Society consensus (2022)
| Group | Range (nmol/L) |
|---|---|
| Rules out Lp(a)-attributable risk (below 30 mg/dL) | <75 |
| Grey zone (30-50 mg/dL) | 75-125 |
| Rules in risk (above 50 mg/dL) | >125 |
| Very high: lifetime risk like untreated familial hypercholesterolaemia (above 180 mg/dL) | >430 |
The consensus gives each cut-off in both units. The 2018 AHA/ACC guideline counts 125 nmol/L or 50 mg/dL as a risk-enhancing factor, and the 2026 guideline keeps it.
nmol/L and mg/dL results come from different assays and are not interchangeable; compare a result only with the cut-offs printed in the same unit.
Units: Some labs report Lp(a) mass in mg/dL instead. The two units measure different things and there is no exact conversion: the 2022 European consensus calls a factor of 2-2.5 (mg/dL to nmol/L) only a best guess and does not recommend converting. [3]
Is there an "optimal" range?
Lp(a) risk rises continuously, so any cut-off is a practical line, not a biological one.
Below 75 nmol/L is low risk
<75 nmol/L (<30 mg/dL)
Labcorp, Quest and the 2022 European consensus
The labs' low-risk band and the consensus rule-out cut-off.
125 nmol/L or 50 mg/dL adds to risk
125 nmol/L or 50 mg/dL or higher
2018 AHA/ACC guideline; kept in the 2026 guideline
A risk-enhancing factor, especially at higher values.
No universal threshold
Risk rises about 11% per 50 nmol/L
AHA scientific statement (2021)
Assay, units, ancestry and the population studied make a single threshold hard to set, so the statement gives a risk adjustment per 50 nmol/L instead.
Sources: [1]
What raises it
| Factor | How | How much |
|---|---|---|
| Inherited LPA gene variantsCondition | More than 90% of Lp(a) level is set by the LPA gene. | No published magnitude [3] [7] |
| Growth hormone therapyHormone | Growth hormone roughly doubled Lp(a) in adults with growth hormone deficiency. | About twice the pretreatment level [4] [3] |
| Kidney disease, pregnancy, hypothyroidismCondition | Nephrotic syndrome raises Lp(a) 3-5 times and pregnancy about 2 times; hypothyroidism raises it. | No published magnitude [3] |
| Replacing saturated fat with carbohydrate or unsaturated fatNutrition | A diet change that lowers LDL can nudge Lp(a) up. | About 10-15% increase [3] |
What lowers it
| Factor | How | How much |
|---|---|---|
| PCSK9 inhibitorsMedication | Evolocumab lowered Lp(a) in the FOURIER trial. | Median -26.9% at 48 weeks [11] |
| NiacinMedication | Extended-release niacin lowered Lp(a) in AIM-HIGH but did not reduce cardiovascular events. | -21% [12] |
| Postmenopausal hormone therapyMedication | Listed in the European consensus among the few factors that lower Lp(a). | About 25% decrease [3] |
Peptides that affect Lp(a)
How each peptide in our library changes Lp(a), from published studies. Lp(a) is mostly genetic, so most results are small or null, and most of the studies are small. None of the FDA labels we checked (GLP-1, tesamorelin, IGF-1 and GnRH drugs) reports Lp(a). No study has measured Lp(a) after dosing Semaglutide, Tirzepatide, Retatrutide, Lixisenatide, Tesamorelin, Sermorelin, CJC-1295, Ipamorelin, GHRP-2 or GHRP-6; PubMed searches for each with lipoprotein(a) find reviews and comparisons of users with non-users, not dosing data.
| Peptide | Effect on Lp(a) | Size of effect | Evidence |
|---|---|---|---|
| Hexarelin | Raises | 6 boys with short stature, intranasal hexarelin 60 micrograms three times daily for 6-9 months: Lp(a) +102% (growth hormone injections raised it 119% and 126% in the same study); no control groupRaising growth hormone raised Lp(a) in one small study in children. [13] | Human trials |
| Nafarelin | Raises | No figure in the abstract: in 34 women with endometriosis on intranasal nafarelin for 24 weeks, Lp(a) rose significantly by week 24 and was back to baseline by the first period after stoppingA temporary rise during treatment. [14] | Human trials |
| Triptorelin | Raises | 10 healthy men with testosterone suppressed by triptorelin for 5 weeks: Lp(a) 278 to 377 U/l (P = 0.004)A rise when testosterone was switched off, in one small study. [15] | Human trials |
| Buserelin | Lowers | No study size in the abstract: in elderly men with prostate cancer, buserelin reduced Lp(a) by 48%The opposite direction to triptorelin and nafarelin. [16] | Human trials |
| Dulaglutide | Lowers | 34 adults with type 2 diabetes, 6 months, no control group: median Lp(a) 12.67 to 11.95 mg/dL (p < 0.05)A statistically significant but small fall in one pilot study. [17] | Human trials |
| IGF-1 (Insulin-Like Growth Factor 1) | Lowers | Recombinant IGF-1 in three small studies with no control group: -66% in Laron syndrome (6-9 months), -18.5% in nine of 10 healthy men (7 days), -48% in 8 people with type 2 diabetes (5 days)Injected IGF-1 lowered Lp(a), the opposite of growth hormone. [13] [18] [19] | Human trials |
| Liraglutide | Lowers | No figure in the abstract: in a randomized trial of 62 adults with type 2 diabetes (liraglutide 1.8 mg vs empagliflozin 25 mg), Lp(a) "improved", with better results on liraglutide; there was no placebo groupThe direction is reported against another diabetes drug; the size is not available in an open source. [20] | Human trials |
| Degarelix | No clear effect | 74 healthy older men on degarelix for about 22 days: Lp(a) 27.0 mg/dL on degarelix alone vs 16.8-23.3 mg/dL with hormone add-back (P = 0.55); there was no pre-degarelix comparisonAdding back testosterone or estradiol made no difference. [21] | Human trials |
| Exenatide | No clear effect | Measured, no change: 211 adults with type 2 diabetes, 30 weeks; cholesterol in Lp(a) changed -0.012 mmol/L (weekly) and -0.023 mmol/L (twice daily), not significantNo change in the one trial that measured it (as Lp(a) cholesterol, not Lp(a) mass). [22] | Human trials |
| Goserelin | No clear effect | Measured, no change: men with prostate cancer (50 treated, 58 controls; 3 months of follow-up) and 15 women with endometriosis treated for 6 monthsTwo studies found no significant effect. [23] [24] | Human trials |
| Insulin | No clear effect | Measured, no change: 60 people with type 2 diabetes starting insulin, 3 months (25.3 vs 25.7 mg/dl), and 54 people, 6 months. A third study of 108 people saw a rise only in those starting below 300 mg/LBetter glucose control on insulin did not move Lp(a) in two studies. [25] [26] [27] | Human trials |
| Leuprolide | No clear effect | Measured, no change: 28 women treated for endometriosis with depot leuprolide for 6 months; Lp(a) did not varyNo change in a randomized endometriosis trial. [28] | Human trials |
| MK-677 (Ibutamoren) | No clear effect | Measured, no change: 24 obese men randomized to MK-677 25 mg daily or placebo for 8 weeks; Lp(a) did not change significantlyThe one randomized trial found no Lp(a) change. [29] | Human trials |
What high or low results can mean
A high result
125 nmol/L or higher is high on Labcorp and Quest reports and a risk-enhancing factor in US guidelines. Above 430 nmol/L (180 mg/dL), lifetime risk is similar to untreated heterozygous familial hypercholesterolaemia. Until outcome trials of specific Lp(a)-lowering drugs report, a high result is a reason to control LDL and other risk factors earlier and more intensively.
- Inherited LPA gene variants
- Kidney disease or nephrotic syndrome
- Pregnancy
- Hypothyroidism
A low result
Below 75 nmol/L (30 mg/dL) rules out Lp(a)-attributable risk in the European consensus. Very low lifelong levels may be linked to diabetes.
- Inherited LPA gene variants
Sources: [3]
How the test works
| Sample | Serum (preferred) or plasma: 1 mL at Labcorp and Quest. |
|---|---|
| Fasting | Not needed. Lp(a) does not change with fasting or a normal meal. Labcorp notes that alcohol, aspirin, niacin and estrogen supplements can distort the result. |
| Timing | Once in adulthood is usually enough: the 2026 ACC/AHA guideline recommends at least one measurement in adulthood, and the 2022 European consensus says at least once in adults, preferably with the first lipid profile. |
| Lab differences | Immunoturbidimetric at Labcorp and Quest, in nmol/L. Results from different assays, and mg/dL versus nmol/L, are not interchangeable. |
| Retesting | One result can differ from the next by up to 20%; the AHA statement suggests averaging two measurements for some patients. |
| Labcorp order code | 120188: Lipoprotein(a) |
| Quest Diagnostics order code | 34604: Lipoprotein (a) |
| LOINC codes |
|
History
Lp(a) was found in 1963 as an inherited serum type; genetics later showed it causes heart disease.
- 1963Kåre Berg identifies Lp(a) as a new inherited serum type in human LDL. [33] [1]
- 1987The apolipoprotein(a) gene sequence turns out to closely resemble plasminogen. [2]
- 2009LPA gene variants that raise Lp(a) are shown to raise coronary risk. [7]
- 2022The European Atherosclerosis Society recommends measuring Lp(a) at least once in all adults. [3]
- 2026The ACC/AHA dyslipidemia guideline recommends at least one Lp(a) measurement in adulthood. [32] [10]
FAQ
What is a normal Lp(a)?
Labcorp and Quest print below 75 nmol/L as low risk or optimal. 75-125 nmol/L is intermediate (moderate at Quest), and 125 or higher is high.
What Lp(a) level is high?
125 nmol/L or 50 mg/dL and above is a risk-enhancing factor in the 2018 AHA/ACC guideline, and the 2026 guideline keeps it. The 2021 AHA scientific statement adds that risk rises continuously, about 11% for every 50 nmol/L, rather than at one line.
Why do some labs use nmol/L and others mg/dL?
They use different assays. nmol/L counts particles, while mg/dL measures mass, which depends on the size of apolipoprotein(a). The 2022 European consensus calls a factor of 2-2.5 only a best guess and does not recommend converting.
Sources: [3]
How often should Lp(a) be tested?
Usually once. The 2026 ACC/AHA guideline recommends at least one measurement in adulthood. One result can differ from the next by up to 20%, so some patients may need two.
Do I need to fast?
No. In 34,829 people, fasting and non-fasting Lp(a) did not differ (median 17.3 vs 19.4 mg/dL).
Sources: [30]
Can diet or exercise lower Lp(a)?
Not meaningfully. Physical activity has little or no effect, and diet changes move it about 10-15% at most, sometimes upward.
Sources: [3]
Is high Lp(a) inherited?
Yes. More than 90% of the level is set by the LPA gene, so relatives often share it; the European consensus suggests offering testing to first-degree relatives.
Sources: [3]
Which peptides lower Lp(a)?
Injected IGF-1 (Insulin-Like Growth Factor 1) lowered it in three small studies without a control group, and Dulaglutide lowered it slightly in one pilot study. Most peptides that were measured, including MK-677 (Ibutamoren) and Insulin, showed no change.
Do growth hormone peptides raise Lp(a)?
Growth hormone itself roughly doubles it, and Hexarelin raised it 102% in one small study in children. The randomized MK-677 (Ibutamoren) trial found no change, and Tesamorelin, Sermorelin, CJC-1295 and Ipamorelin have no Lp(a) data.
References
- Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(1):e48-e60. PMID 34647487
- McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330(6144):132-7. PMID 3670400
- Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-3946. PMID 36036785
- Edén S, Wiklund O, Oscarsson J, et al. Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler Thromb. 1993;13(2):296-301. PMID 8427864
- Labcorp. Test 120188: Lipoprotein(a). Methodology, specimen, patient preparation, limitations and LOINC map. labcorp.com/tests/120188/lipoprotein-a
- Quest Diagnostics. Test 34604: Lipoprotein (a). Test directory: methodology, specimen, LOINC and risk categories. testdirectory.questdiagnostics.com/test/test-detail/34604/lipoprotein-a?cc=PHP
- Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518-28. PMID 20032323
- Labcorp. Sample report, test 120188 (Lipoprotein (a)): reference interval and risk categories as printed for a 35-year-old man (reported 03/25/2026). files.labcorp.com/testmenu-d8/sample_reports/120188.pdf
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. PMID 30586774
- Sabouret P, Mafrica D, Giamundo DM, et al. The 2026 ACC/AHA Dyslipidemia Guideline: A Critical and Transatlantic Perspective on Personalized Lipid Management. Life (Basel). 2026;16(9). PMID 42795336
- O'Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2019;139(12):1483-1492. PMID 30586750
- Albers JJ, Slee A, O'Brien KD, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol. 2013;62(17):1575-9. PMID 23973688
- Laron Z, Wang XL, Klinger B, et al. Growth hormone increases and insulin-like growth factor-I decreases circulating lipoprotein(a). Eur J Endocrinol. 1997;136(4):377-81. PMID 9150696
- Kurabayashi T, Takakuwa K, Tanaka K. Treatment with nafarelin for endometriosis in young women. Efficacy, safety and lipid metabolism. Niigata Nafarelin Study Group. J Reprod Med. 2000;45(6):454-60. PMID 10900577
- Hislop MS, St Clair Gibson A, Lambert MI, et al. Effects of androgen manipulation on postprandial triglyceridaemia, low-density lipoprotein particle size and lipoprotein(a) in men. Atherosclerosis. 2001;159(2):425-32. PMID 11730823
- Arrer E, Jungwirth A, Mack D, et al. Treatment of prostate cancer with gonadotropin-releasing hormone analogue: effect on lipoprotein[a]. J Clin Endocrinol Metab. 1996;81(7):2508-11. PMID 8675568
- Hachuła M, Kosowski M, Basiak M, et al. Influence of Dulaglutide on Serum Biomarkers of Atherosclerotic Plaque Instability: An Interventional Analysis of Cytokine Profiles in Diabetic Subjects-A Pilot Study. Medicina (Kaunas). 2024;60(6). PMID 38929525
- Oscarsson J, Lundstam U, Gustafsson B, et al. Recombinant human insulin-like growth factor-I decreases serum lipoprotein(a) concentrations in normal adult men. Clin Endocrinol (Oxf). 1995;42(6):673-6. PMID 7634511
- Zenobi PD, Holzmann P, Glatz Y, et al. Improvement of lipid profile in type 2 (non-insulin-dependent) diabetes mellitus by insulin-like growth factor I. Diabetologia. 1993;36(5):465-9. PMID 8314453
- Bechlioulis A, Markozannes G, Chionidi I, et al. The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: A randomized, prospective, intervention study. J Diabetes Complications. 2023;37(4):108436. PMID 36842186
- Roelfsema F, Yang RJ, Veldhuis JD. Estradiol Does Not Influence Lipid Measures and Inflammatory Markers in Testosterone-Clamped Healthy Men. J Endocr Soc. 2018;2(8):882-892. PMID 30057969
- Chiquette E, Toth PP, Ramirez G, et al. Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers. Vasc Health Risk Manag. 2012;8:621-9. PMID 23166441
- Denti L, Pasolini G, Cortellini P, et al. Effects of androgen suppression by gonadotropin-releasing hormone agonist and flutamide on lipid metabolism in men with prostate cancer: focus on lipoprotein(a). Clin Chem. 1996;42(8 Pt 1):1176-81. PMID 8697573
- Anastasilakis AD, Polyzos SA, Vorkas PA, et al. Lipid Profile after Pharmacologic Discontinuation and Restoration of Menstruation in Women with Endometriosis: A 12-Month Observational Prospective Study. J Clin Med. 2023;12(16). PMID 37629472
- Caixas A, Pérez A, Qrdóñez-Llanos J, et al. Lack of change of lipoprotein(a) levels by the optimization of glycemic control with insulin therapy in NIDDM patients. Diabetes Care. 1997;20(9):1459-61. PMID 9283797
- Wolffenbuttel BH, Leurs PB, Sels JP, et al. Improved blood glucose control by insulin therapy in type 2 diabetic patients has no effect on lipoprotein(a) levels. Diabet Med. 1993;10(5):427-30. PMID 8334821
- Kuusi T, Yki-Järvinen H, Kauppinen-Mäkelin R, et al. Effect of insulin treatment on serum lipoprotein(a) in non-insulin-dependent diabetes. Eur J Clin Invest. 1995;25(3):194-200. PMID 7781667
- Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: a multicenter, randomized, double-blind study. Gestrinone Italian Study Group. Fertil Steril. 1996;66(6):911-9. PMID 8941054
- Svensson J, Jansson JO, Ottosson M, et al. Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a). J Clin Endocrinol Metab. 1999;84(6):2028-33. PMID 10372705
- Langsted A, Kamstrup PR, Nordestgaard BG. Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk. Atherosclerosis. 2014;234(1):95-101. PMID 24632508
- Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J. 2016;37(25):1944-58. PMID 27122601
- Writing Committee Members, Blumenthal RS, Morris PB, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17):e1154-e1276. PMID 41824552
- BERG K. A NEW SERUM TYPE SYSTEM IN MAN--THE LP SYSTEM. Acta Pathol Microbiol Scand. 1963;59:369-82. PMID 14064818
Educational information, not medical advice. Lab ranges and test codes were checked on November 2, 2026. Always use the range printed on your own report, and talk to a clinician about your results.